Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.71 +1.1%	$4.24	$2.90 ▼ $11.16	$323.90M	-0.01	2.90 million shs	4.00 million shs
CNTX Context Therapeutics	$0.85 -0.9%	$0.75	$0.49 ▼ $2.59	$77.15M	1.89	180,384 shs	90,745 shs
DMAC DiaMedica Therapeutics	$5.87 -1.8%	$4.62	$3.19 ▼ $6.82	$309.10M	1.25	322,110 shs	307,921 shs
FHTX Foghorn Therapeutics	$5.01 -7.4%	$5.31	$2.94 ▼ $10.25	$305.83M	3.05	96,706 shs	94,366 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+6.69%	+1.10%	-8.93%	-34.58%	-45.22%
CNTX Context Therapeutics	+0.06%	-4.95%	+1.18%	+39.34%	-65.60%
DMAC DiaMedica Therapeutics	-1.16%	-0.33%	+18.18%	+42.72%	+51.39%
FHTX Foghorn Therapeutics	-2.17%	+2.85%	-16.77%	+25.23%	-31.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	3.3375 of 5 stars	4.3	3.0	2.4	1.7	0.6
CNTX Context Therapeutics	3.5713 of 5 stars	3.6	4.0	3.2	1.7	1.3
DMAC DiaMedica Therapeutics	1.4779 of 5 stars	3.5	0.0	2.5	1.7	0.0
FHTX Foghorn Therapeutics	3.0684 of 5 stars	3.6	3.0	3.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.57	Moderate Buy	$17.40	369.00% Upside
CNTX Context Therapeutics	3.17	Buy	$5.25	516.05% Upside
DMAC DiaMedica Therapeutics	3.00	Buy	$12.33	110.11% Upside
FHTX Foghorn Therapeutics	3.17	Buy	$10.67	112.91% Upside

Current Analyst Ratings Breakdown

Latest CNTX, DMAC, FHTX, and ALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
8/13/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
8/13/2025	ALT Altimmune	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $24.00
8/13/2025	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
8/7/2025	CNTX Context Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
8/7/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
7/18/2025	DMAC DiaMedica Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $14.00
7/18/2025	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $11.00
7/18/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
7/10/2025	ALT Altimmune	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
7/10/2025	ALT Altimmune	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$25.00 ➝ $15.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	16,372.23	N/A	N/A	$1.83 per share	2.03
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.92 per share	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$0.53 per share	N/A
FHTX Foghorn Therapeutics	$22.60M	12.53	N/A	N/A	($1.36) per share	-3.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$95.06M	-$1.18	0.00	N/A	N/A	-438,730.03%	-62.63%	-55.29%	11/11/2025 (Estimated)
CNTX Context Therapeutics	-$26.73M	-$0.36	0.00	N/A	N/A	N/A	-38.80%	-37.53%	11/5/2025 (Estimated)
DMAC DiaMedica Therapeutics	-$24.44M	-$0.69	N/A	N/A	N/A	N/A	-78.99%	-69.94%	11/12/2025 (Estimated)
FHTX Foghorn Therapeutics	-$86.62M	-$1.19	0.00	N/A	N/A	-311.90%	N/A	-28.00%	11/3/2025 (Estimated)

Latest CNTX, DMAC, FHTX, and ALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ALT Altimmune	-$0.32	-$0.27	+$0.05	-$0.27	$0.00 million	$0.01 million
8/12/2025	Q2 2025	DMAC DiaMedica Therapeutics	-$0.18	-$0.18	N/A	-$0.18	N/A	N/A
8/6/2025	Q2 2025	CNTX Context Therapeutics	-$0.06	-$0.09	-$0.03	-$0.09	N/A	N/A
8/5/2025	Q2 2025	FHTX Foghorn Therapeutics	-$0.31	-$0.28	+$0.03	-$0.28	$7.62 million	$7.56 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	0.09	20.44	20.44
CNTX Context Therapeutics	N/A	19.09	19.09
DMAC DiaMedica Therapeutics	N/A	7.55	7.55
FHTX Foghorn Therapeutics	N/A	2.62	2.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
CNTX Context Therapeutics	14.03%
DMAC DiaMedica Therapeutics	10.12%
FHTX Foghorn Therapeutics	61.55%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.40%
CNTX Context Therapeutics	2.80%
DMAC DiaMedica Therapeutics	7.30%
FHTX Foghorn Therapeutics	7.58%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	88.26 million	84.37 million	Optionable
CNTX Context Therapeutics	7	89.70 million	87.19 million	Not Optionable
DMAC DiaMedica Therapeutics	20	51.69 million	47.92 million	Optionable
FHTX Foghorn Therapeutics	120	56.53 million	52.25 million	Optionable

CNTX, DMAC, FHTX, and ALT Headlines

Recent News About These Companies

Foghorn Therapeutics to Participate in Key Upcoming Healthcare Conferences in September 2025

August 27 at 7:51 AM | quiverquant.comQ

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

August 27 at 7:00 AM | globenewswire.com

Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why

August 25 at 1:01 PM | zacks.com

Equities Analysts Issue Forecasts for FHTX Q3 Earnings

August 9, 2025 | marketbeat.com

Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing

August 8, 2025 | zacks.com

Q3 EPS Forecast for Foghorn Therapeutics Boosted by Analyst

August 8, 2025 | marketbeat.com

Equities Analysts Set Expectations for FHTX Q1 Earnings

August 7, 2025 | marketbeat.com

Foghorn Therapeutics (FHTX) Expected to Announce Earnings on Thursday

August 7, 2025 | marketbeat.com

Foghorn Therapeutics (NASDAQ:FHTX) Announces Quarterly Earnings Results

August 6, 2025 | marketbeat.com

Is Foghorn Therapeutics (NASDAQ:FHTX) In A Good Position To Invest In Growth?

August 5, 2025 | finance.yahoo.com

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates

August 5, 2025 | zacks.com

Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update

August 5, 2025 | globenewswire.com

Foghorn Therapeutics Inc (FHTX) - Investing.com

July 3, 2025 | investing.com

Foghorn Therapeutics Inc. to Participate in Major Upcoming Healthcare Conferences in 2025

May 22, 2025 | quiverquant.comQ

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

May 22, 2025 | globenewswire.com

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates

May 14, 2025 | zacks.com

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

May 14, 2025 | globenewswire.com

Why Foghorn Therapeutics Inc.’s (FHTX) Stock Is Up 5.95%

May 13, 2025 | aaii.comA

Why Foghorn Therapeutics Inc.’s (FHTX) Stock Is Down 5.19%

May 9, 2025 | aaii.comA

Foghorn Therapeutics’ SWOT analysis: chromatin pioneer’s stock faces clinical hurdles

May 7, 2025 | investing.com

Why Foghorn Therapeutics Inc.’s (FHTX) Stock Is Down 8.12%

May 7, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CNTX, DMAC, FHTX, and ALT Company Descriptions

Altimmune NASDAQ:ALT

$3.71 +0.04 (+1.09%)

Closing price 04:00 PM Eastern

Extended Trading

$3.71 0.00 (0.00%)

As of 07:59 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Context Therapeutics NASDAQ:CNTX

$0.85 -0.01 (-0.91%)

Closing price 04:00 PM Eastern

Extended Trading

$0.86 +0.01 (+1.50%)

As of 07:39 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

DiaMedica Therapeutics NASDAQ:DMAC

$5.87 -0.11 (-1.84%)

Closing price 04:00 PM Eastern

Extended Trading

$6.00 +0.13 (+2.20%)

As of 06:55 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Foghorn Therapeutics NASDAQ:FHTX

$5.01 -0.40 (-7.39%)

Closing price 04:00 PM Eastern

Extended Trading

$5.01 0.00 (0.00%)

As of 06:33 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time